LOGIN  |  REGISTER
Chimerix
Assertio

Stevanato to Participate in Upcoming Investor Conferences

May 09, 2025 | Last Trade: US$25.16 0.84 3.45

PIOMBINO DESE, Italy / May 09, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences.

  • Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas
  • Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentation at the 45th Annual William Blair Growth Stock Conference in Chicago
  • Thursday, June 5, 2025, at 10:30 a.m. (ET) – Fireside chat at the Jefferies Global Healthcare Conference in New York City

A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients.

For more information, please visit: www.stevanatogroup.com.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page